Apellis Pharmaceuticals Inc. (APLS)
Bronstein, Gewirtz & Grossman, LLC Is Investigating Apellis Pharmaceuticals, Inc. (APLS) And Encourages Stockholders to Connect
NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS). Investors who purchased Apellis securities prior to January 28, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLS.
Apellis Pharmaceuticals, Inc. (APLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESSWIRE / January 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS). Investors who purchased Apellis securities prior to January 28, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLS.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Apellis Pharmaceuticals, Inc. (APLS) and Encourages Stockholders to Learn More About the Investigation
NEW YORK, NY / ACCESSWIRE / January 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS). Investors who purchased Apellis securities prior to January 28, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLS.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Apellis Pharmaceuticals, Inc. (APLS) And Encourages Investors to Reach Out
NEW YORK, NY / ACCESSWIRE / January 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS). Investors who purchased Apellis securities prior to January 28, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLS.
Why Is Apellis Pharmaceuticals (APLS) Up 18.4% Since Last Earnings Report?
Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock?
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y
APLS' earnings and revenues miss third-quarter 2024 estimates. Syfovre drives revenues year over year.
Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday
Sales of the company's top commercialized product didn't meet expectations.
Apellis Pharmaceuticals, Inc. (APLS) Q3 2024 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Meredith Kaya - Senior Vice President of Investor Relations and Strategic Finance Cedric Francois - Co-Founder and Chief Executive Officer Adam Townsend - Chief Operating Officer Caroline Baumal - Chief Medical Officer Tim Sullivan - Chief Financial Officer Conference Call Participants Jonathan Miller - Evercore Tazeen Ahmad - Bank of America Anupam Rama - JPMorgan Salveen Richter - Goldman Sachs Yigal Nochomovitz - Citigroup Nicholas Econom - Raymond James Phil Nadeau - TD Cowen Katherine Wang - Jefferies Ellie Merle - UBS Annabel Samimy - Stifel Douglas Tsao - H.C. Wainwright Lachlan Hanbury-Brown - William Blair Derek Archila - Wells Fargo Biren Amin - Piper Sandler Lisa Walter - RBC Greg Harrison - Scotiabank Graig Suvannavejh - Mizuho Securities Laura Chico - Wedbush Securities Operator Good morning, ladies and gentlemen.
Apellis Pharmaceuticals (APLS) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Apellis Pharmaceuticals (APLS) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Lags Revenue Estimates
Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $1.17 per share a year ago.
Will Apellis Pharmaceuticals, Inc. (APLS) Report Negative Earnings Next Week? What You Should Know
Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch
William Blair has initiated coverage on Apellis Pharmaceuticals, Inc. APLS and notes that Apellis was the first company to successfully target complement C3, which has led to the approval of two therapies: Empaveli (systemic pegcetacoplan) for paroxysmal nocturnal hemoglobinuria and Syfovre (intravitreal pegcetacoplan) for geographic atrophy secondary to age-related macular degeneration.
